Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Harlan Waksal currently holds 536,966 shares of Lyra Therapeutics, Inc. (LYRA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Harlan Waksal has been a net buyer of LYRA stock. They have purchased $1.5M and sold $0 worth of shares.
Harlan Waksal's most recent insider trade was on Dec 9, 2024, when they sold 128,333 shares at $0.00 per share.
Harlan Waksal serves as Executive at Lyra Therapeutics, Inc. (LYRA). They have executed 23 insider transactions totaling $1.5M over their tenure at the company.
Harlan Waksal holds the position of Executive at Lyra Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 17 years and currently hold a stake valued at $0.
Harlan Waksal has shown a buying trading pattern, with $1.5M in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Harlan Waksal was on Nov 9, 2021, when they sold $1.7M worth of KDMN shares. This transaction involved 177,945 shares at $9.50 per share.
Harlan Waksal currently owns 536,966 shares of Lyra Therapeutics, Inc. (LYRA), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Harlan Waksal's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Harlan Waksal has 23 Form 4 filings on record as an insider at Lyra Therapeutics, Inc..
Set alerts for Harlan Waksal and 40,000+ other insiders.